NCT06342908View on ClinicalTrials.gov

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

March 8, 2027

Study Completion Date

January 9, 2028

Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood and stool sample collection

BIOLOGICAL

Dendritic Cell Therapy

Given PpDC vaccine ID

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Poly ICLC

Given IM

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER